Companies in #Tumor Microenvironment Modulation
Found 1 company operating in this sector.
Propanc Biopharma is a clinical-stage biopharmaceutical company developing a pipeline of proenzyme-based oncology therapeutics designed to suppress tumor growth and metastasis by targeting and modulating the tumor microenvironment. Lead candidate PRP is being advanced in metastatic colorectal and pancreatic cancers. The company is pursuing an OPAL (Opposite-Pole) technology platform based on the proenzyme theory of cancer.